Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Ipca Laboratories Ltd

    IPCA was incorporated as 'The Indian Pharmaceutical Combine Association Limited.' in October 1949. The present management took over in November 1975 when the total turnover of t

  • No Image
    Ivee Injecta Ltd

    Ivee Injectaa Limited is engaged in the manufacture of Large Volume Parenterals (LVPs) and diversifying into manufacture of Small Volume Parenterals (SVPs) and other allied acti

  • No Image
    Jagsonpal Pharmaceuticals Ltd

    Jagsonpal is among India?s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities.